title: Mining and modeling human genetics for autism therapeutics.
abstract: A growing understanding of the genetic origins of autism spectrum disorders (ASDs) and the impact of ASD risk genes on synaptic function presents new opportunities for drug discovery. Large-scale human genetics studies have begun to reveal molecular pathways and potential therapeutic drug targets. Subsequent validation and characterization of ASD risk genes in mouse models holds promise for defining relevant cellular mechanisms and brain circuits associated with the core behavioral symptoms of autism. Here we review recent advances in the molecular therapeutics in ASDs and discuss opportunities and obstacles for converting emerging biology into new medicines. We present emerging concepts on the impact of risk genes during development and adulthood that define points of intervention. We further highlight ongoing clinical trials in patients with syndromic forms of autism. These clinical studies will be an important test of the utility of human genetics as a starting point for drug discovery in ASDs.
authors.affiliation: Pfizer Worldwide Research and Development, Neuroscience Research Unit, Groton, CT 06340, USA. daniel.g.smith@pfizer.com
authors.forename: Daniel G
authors.initials: DG
authors.lastname: Smith
authors.forename: Michael D
authors.initials: MD
authors.lastname: Ehlers
mesh_terms: D000818:Animals; D001321:Autistic Disorder / Q000235:genetics* / Q000628:therapy*; D004195:Disease Models, Animal; D020022:Genetic Predisposition to Disease; D005826:Genetics, Medical; D006801:Humans; D051379:Mice